Genentech to operate at near-capacity to satisfy clamor for its drugs

06/27/2005 | Reuters

Demand for Genentech's highly successful drugs, such as Avastin, has caused the company to operate at near-capacity and has led the company to cancel a separate deal with Amgen to manufacture that firm's products. Genentech's senior vice president of product operations said he does not like operating at capacity "for an extended period of time," but the company's plan is to do that for some time, while making additional operational capacity available.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN